---
title: Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <em>BRAF</em>
  V600-Mutant Pediatric High-Grade Glioma
date: '2023-08-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37643378/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230829193420&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: In relapsed/refractory BRAF V600-mutant pHGG, dabrafenib
  plus trametinib improved ORR versus previous trials of chemotherapy in molecularly
  unselected patients with pHGG and was associated with durable responses and encouraging
  survival. These findings suggest that dabrafenib plus trametinib is a promising
  targeted therapy option for children and adolescents with relapsed/refractory BRAF
  V600-mutant ...'
disable_comments: true
---
CONCLUSION: In relapsed/refractory BRAF V600-mutant pHGG, dabrafenib plus trametinib improved ORR versus previous trials of chemotherapy in molecularly unselected patients with pHGG and was associated with durable responses and encouraging survival. These findings suggest that dabrafenib plus trametinib is a promising targeted therapy option for children and adolescents with relapsed/refractory BRAF V600-mutant ...